Categories

PAHO will support Dominican Republic public health system

[Original text in Spanish]

President Danilo Medina received today the visit of the director of the Pan American Health Organization (PAHO), Carissa Etienne, in which they discussed the progress and challenges of the health sector in the Dominican Republic.

Along with Etienne, was Alma Morales Salinas who, on behalf of the director of PAHO, explained the interest of that organization in supporting the public health system of the country, making available technical cooperation to address noncommunicable diseases.

He also said that PAHO will support the Dominican Republic in what it requires for the development of the health city within the framework of strengthening the integrated health service networks.

The meeting was framed in the meeting of managers of the PAHO sub-region, as well as the subregion of Central America, Cuba, Mexico and the Dominican Republic and heads of departments of the regional headquarters of that organization.

For more information go to: https://presidencia.gob.do/noticias/salud-grandes-avances-y-retos-ops-apoyara-sistema-de-salud-publica-y-9-1-1

 
Categories

Ecuador: ARCSA – Alert on illegitimate lots of medicines COPAXONE, TASIGNA, AVASTIN and KIVEXA

The National Agency of Health Regulation, Control and Surveillance (Arcsa) informs the Ecuadorian population of the alert published by the National Administration of Medicines, Food and Medical Technology (ANMAT) of Argentina, which informs the population that has been detected the existence of medicinal specialties:

• COPAXONE 40 mg / ml, active ingredient Glatiramer Acetate. Lot C42234. Exp. 04/2018.
• TASIGNA, active ingredient Nilotinib Chloride 200 mg, 112 capsules. Lot SF432. Exp 06/2019.
• AVASTIN, active ingredient Bevacizumab 400 mg / ml, per 1 vial for I.V. after dissolution. Lot H179810. Exp. 02/2018.
• KIVEXA for 30 coated tablets, orally. Lot KC7W. Exp. 10/2019.

The warning arises as a result of having conducted a series of raids in different cities of Argentina, during which units were removed from the items detailed in sample character. After the relevant verifications were made to the respective registry holders, it could be verified that they are illegitimate.

For more information go to http://www.controlsanitario.gob.ec/alerta-sobre-lotes-ilegitimos-de-medicamentos-copaxone-tasigna-avastin-y-kivexa/

 
Categories

Colombia: Invima Alert No. 010-2018 – “Vita-Gest”. Product with false marketing authorization

Bogotá, February 15, 2018

Product name: Vita-Gest

Sanitary registry: RSAD16I47707 false  marketing authorization (registry)

Commercial presentation: Bottle for 700 grams

Manufacturer (s) / Importer (s): “Laboratorio Salud Natural”

Source:  https://www.invima.gov.co/alimentos-y-bebidas-aler-sani/alerta-sanitaria-numero-010-2018-vita-gest-pdf/download.html

 
Categories

President Tabaré Vázquez of Uruguay is a co-chair of The WHO Independent Global High-level Commission on noncommunicable diseases

16 February 2018 | Geneva – WHO is announcing today a new high-level commission, comprised of heads of state and ministers, leaders in health and development and entrepreneurs. The group will propose bold and innovative solutions to accelerate prevention and control of the leading killers on the planet – noncommunicable diseases (NCDs) like heart and lung disease, cancers, and diabetes.

The WHO Independent Global High-level Commission on NCDs is co-chaired by President Tabaré Vázquez of Uruguay; President Maithripala Sirisena of Sri Lanka; President Sauli Niinistö of Finland; Veronika Skvortsova, Minister of Healthcare of the Russian Federation; and Sania Nishtar, former Federal Minister of Pakistan.

(…)

The new Commission was established by WHO Director-General Dr Tedros Adhanom Ghebreyesus and runs until October 2019. It will provide actionable recommendations to contribute to the Third United Nations General Assembly High-level Meeting on NCDs scheduled for the second half of 2018. This will include the submission of its first report to Dr Tedros in early June.

(…)

For more information go to http://www.who.int/mediacentre/news/releases/2018/world-leaders-ncds/en/

 
Categories

TECENTRIQ (atezolizumab) – Risk of Myocarditis

Audiences

Healthcare professionals including oncologists, uro-oncologists, urologists, oncology nurses, oncology pharmacists, emergency room staff, and other healthcare professionals providing care to cancer patients, including those working in hospitals, cancer centers, oncology clinics, and pharmacies.

Key messages

  • Severe cases of myocarditis have been reported in patients being treated with TECENTRIQ (atezolizumab) in clinical trials.
  • Healthcare professionals are advised to:
    • monitor patients receiving TECENTRIQ for signs and symptoms of myocarditis.
    • withhold TECENTRIQ therapy in patients with Grade 2 myocarditis.
    • permanently discontinue TECENTRIQ treatment in patients with Grade 3 or 4 myocarditis.
    • administer corticosteroids and/or additional immunosuppressive agents as clinically indicated to TECENTRIQ treated patients who develop myocarditis.
  • The Canadian Product Monograph has been updated to include this new safety information.

For more information go to http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/65990a-eng.php

Posting date: February 14, 2018

 
Categories

Mexico promotes opportunities for expansion and access to the pharmaceutical and medical device market

As part of the strategy to strengthen links at a global level, the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) participated in the work of India Pharma 2018, where it presented the regulatory advances reported by Mexico to expedite the population’s access to medicines and supplies for quality, safety and efficacy.

For more information go to https://www.gob.mx/cofepris/articulos/fortalece-la-cofepris-vinculos-internacionales-147624?idiom=es

 
Categories

MEDICC Review interview Director of CECMED, Cuba

Science at the Service of Public Health: Rafael Pérez Cristiá MD PhD Center for State Control of Medicines and Medical Devices.

(…)

Cuba’s nascent biotechnology sector began making scientific breakthroughs in the 1980s, including the isolation of human leukocyte interferon alpha (1981) and the development of the world’s first safe, effective meningitis BC vaccine (1989). With positive results in hand and a growing R&D pipeline, the island nation established a national regulatory authority (NRA) to implement and oversee best practices for all pharmaceuticals and medical devices, domestically produced and imported, used in the country’s universal health system. Founded in 1989, Cuba’s Center for State Control of Medicines and Medical Devices (CECMED) is the entity charged with regulating all phases of scientific innovation for health, from clinical trial design to postmarketing surveillance.

(…)

For more information go to: http://www.cecmed.cu/content/entrevista-de-medicc-review-director-del-cecmed-science-service-public-health-rafael-perez

 
Categories

ANMAT DETECTS COUNTERFEIT LOTS OF VARIOUS MEDICINES

Argentina, February 7, 2018 [Source in Spanish]

The ANMAT, National Regulatory Authority of Argentina, informs the population that the existence of counterfeit lots of the following medicinal specialties has been detected:

  • ISENTRESS Raltegravir 400 mg, for 60 coated tablets. Lot ARG0324 / L026309 vto. ABR / 2018.
  • PERUGE Pertuzumab 420 mg / 14 ml, for 1 concentrated vial for solution for infusion. Lot H0109918 vto. 10/2019.
  • VIRORREBER 600 Efavirenz 600 mg, for 30 coated tablets. Lot MEG35IK4 Vto. 02/19.

The warning arises as a result of having carried out a series of inspections in different cities of the country, during which units of the items detailed in sample were withdrawn. After the relevant verification were made to the respective marketing authorization holders, it could be verified that they are illegitimate.

Because of the above, and taking into account that the other units in question could have a valid expiration date and could be found in the market, the population is warned to refrain from consuming them and, if they have any of them in their possession, contact the “ANMAT Responde” Program (toll free: 0-800-333-1234; mail: respuesta@anmat.gov.ar).

Source in Spanish: http://www.anmat.gov.ar/comunicados/Isentress-Perjeta-Virorreber%2006-02-18.pdf

 

 
Categories

Dominican Republic: Vice-president, Minister of Health walk through new construction Hemocentro

Santo Domingo.- The Vice-President of the Republic, Margarita Cedeño de Fernández and the Minister of Health, Altagracia Guzmán Marcelino, made a tour on Monday to verify the progress made in the construction work of the new Hemocentro. They made the tour accompanied by other personalities.

More information through the link http://www.msp.gob.do/Vice-presidenta-Ministra-de-Salud-recorren-construccion-nuevo-Hemocentro